Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AxoGen, Inc.
Addressing health care inequities, providing a nurturing environment for employees and learning from the pandemic were among the aims expressed by executives surveyed by Scrip.
Biopharma industry leaders highlight key concerns and opportunities across production, supply chain and commercial operations. Business transformation is top of mind for many, perhaps unsurprisingly following two years of rapid and mostly successful adaptation to the strictures of the COVID-19 pandemic.
Five-month drought broken by ExCellThera’s "optimized culture system" designation for treatment of hematologic malignancies. The Pink Sheet details each of the 27 announced Regenerative Medicine Advanced Therapy designations in a table.
The study will be expanded by 50 patients, for a total of 220 subjects, based on the recommendation of a statistician who reviewed an interim analysis. RECON is intended to support a Biologic License Application for Avance, a processed human nerve allograft for bridging severed peripheral nerves.
- Implantable Devices